According to a research report “ Contract Development And Manufacturing Organization Outsourcing Market” by Product (Small molecules, Biologics) Service (API/bulk drugs, Drug product manufacturing, Packaging) Geography (North America, Europe, APAC, South America, Middle East and Africa)- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 136.9 billion, at a CAGR of 17.01% during the forecast period. The pharmaceutical industry is experiencing significant growth due to demographic trends and increasing prevalence of chronic diseases. In the US, the population aged 65 and above is projected to comprise approximately 20% of the total population by 2025, driven by the aging baby boomer generation. Furthermore, non-communicable diseases such as diabetes and obesity, largely attributed to unhealthy lifestyles, are on the rise, affecting one-third of adults globally. These conditions can lead to more complex health issues, including heart diseases, thereby boosting pharmaceutical sales and demand for Contract Development and Manufacturing Organizations (CDMOs) to produce and supply essential medications..
Browse market data tables, figures, and in-depth TOC on “Contract Development And Manufacturing Organization Outsourcing Market” by Product (Small molecules, Biologics) Service (API/bulk drugs, Drug product manufacturing, Packaging) Geography (North America, Europe, APAC, South America, Middle East and Africa) Global Forecast to 2028. Download Free Sample
By Product, the Small molecules segment is projected to dominate the market size in 2024
Contract Development and Manufacturing Organizations (CDMOs) outsourcing market growth is driven by the increasing trend of businesses to focus on core competencies and reduce operational costs. CDMOs offer specialized expertise, advanced technologies, and economies of scale, making them an attractive option for pharmaceutical and biotech companies looking to bring their products to market efficiently. This outsourcing model enables faster time-to-market, improved product quality, and reduced risk.
By Service, API/bulk drugs segment is expected to hold the largest market size for the year 2024
Contract Development and Manufacturing Organizations (CDMOs) outsourcing market refers to the engagement of pharmaceutical and biotech companies with external entities for the development and manufacturing of their products. This partnership enables businesses to reduce costs, improve efficiency, and focus on core competencies, while CDMOs leverage their expertise and resources to deliver high-quality solutions. The global CDMO outsourcing market is poised for significant growth due to increasing R&D expenditures, regulatory compliance demands, and the need for faster time-to-market.
North America is forecasted to hold the largest market size by region in 2024
As a seasoned business advisor, I'm here to provide insights on the Contract Development and Manufacturing Organization (CDMO) outsourcing market. This sector experiences significant growth due to increasing industry competition and the need for cost savings and operational efficiency. CDMOs offer specialized expertise, enabling businesses to focus on core competencies while outsourcing complex manufacturing processes. By leveraging CDMOs' advanced technologies and capabilities, companies can accelerate time-to-market and improve product quality. This strategic outsourcing trend is expected to continue, as businesses seek to remain competitive and agile in today's dynamic market landscape.
The Contract Development And Manufacturing Organization Outsourcing Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Contract Development and Manufacturing Organization (CDMO) outsourcing market is experiencing significant growth, particularly in the areas of monoclonal antibodies, vaccinations, insulin, and other biologics. Pharmaceutical innovators and big pharma are turning to CDMOs for custom solutions in the development and manufacturing of complex products such as monoclonal antibodies used in cancer treatments and vaccines for chronic diseases. CDMOs play a crucial role in the production of critical drugs like insulin, as well as in the development of biosimilars, which offer affordable alternatives to branded biologics. CDMOs also provide expertise in the manufacturing of complex drug delivery systems, such as microcaps, autoinjectors, and prefilled syringes, used in the delivery of vaccinations and other therapies. Leading CDMOs like Lifera, MIR, and RA Chem, among others, have been attracting significant funding from investors such as Samara Capital, PAG, Advent, and The Carlyle Group. The CDMO market is expected to continue growing, driven by the increasing demand for contract research, contract manufacturing, and drug development services from pharmaceutical firms. The market for small molecules and biologics is expected to reach USD175 billion by 2025, with a significant portion of that revenue coming from CDMOs. Clinical trials for drugs like Aflibercept and biosimilars for generic drugs are also driving demand for CDMO services.
Market Research Overview
The Contract Development and Manufacturing Organization (CDMO) outsourcing market is witnessing significant growth in the converting, coating, blending, and analytical services segments, particularly in the pharmaceutical and biotechnology industries. Companies like Arranna Bio, Lifera, and AP Biologics specialize in monoclonal antibodies, vaccinations, insulin, and microcaps for medication development. The CDMO presence is crucial for big pharma in the production of chronic diseases treatments, including drugs for cancer, Alzheimer's, and diabetes. The market's revenue stream is driven by the outsourcing of pharmaceutical research, economic instability, and intellectual property considerations. The submarkets of quality control, custom solutions, and biosimilars are also gaining traction. The CDMO market caters to various sectors, such as vaccinations, insulin production, and personalized medicine for the geriatric population. The use of sophisticated technology and time efficiency are essential factors in the global biopharmaceutical market. Strategic transactions, such as the Union Cabinet's approval of AbbVie's acquisition of Allergan's generic drugs business, demonstrate the importance of CDMOs in the pharmaceutical industry. CDMOs offer contract packaging, injectable capabilities, and quality testing services, making them indispensable partners for pharmaceutical innovators. The market includes players like Samara Capital, PAG, RA Chem, Advent, and The Carlyle Group, which focus on small molecules and biologics production, clinical trials, and funding. The production of biosimilars, such as Aflibercept, and the development of autoinjectors and prefilled syringes are also significant areas of growth. In conclusion, the CDMO outsourcing market plays a vital role in the pharmaceutical industry, particularly in the production of chronic illness treatments and the development of biosimilars and personalized medicine. The market's growth is driven by the need for cost-effective manufacturing, strategic transactions, and the increasing demand for sophisticated technology and time efficiency.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
